# Hikma Pharmaceuticals USA, Inc.: Midazolam Hydrochloride Injection shortage reverified (available from this maker)

**Score:** 35/100

| Field | Value |
|---|---|
| Manufacturer | Hikma Pharmaceuticals USA, Inc. |
| Drug | Midazolam Hydrochloride Injection |
| Dosage form | Injection |
| Therapeutic category | Anesthesia, Neurology |
| Status | Current |
| Stage | Shortage reverified (still listed) |
| Availability | Available |
| Presentations affected | 5 |
| Package NDCs | 0641-6056-10, 0641-6060-10, 0641-6059-01, 0641-6061-25, 0641-6057-25 |
| Manufacturer supply note | Additional lots are scheduled to be manufactured. Product will be made available as it is released. |
| First posted | 2020-04-02 |
| Updated | 2026-10-14 |

## Why this score
- Sterile injectable: hospital and 503B demand.

Source: openFDA drug shortages endpoint (U.S. Food and Drug Administration drug shortage list) (https://dps.fda.gov/drugshortages). Last refreshed: 2026-11-04T06:10:12.565Z.
From the openFDA drug shortages endpoint, which mirrors the FDA drug shortage list and can lag it by days. Availability and recovery notes are the manufacturer's own statements to FDA. Company and product level only. Verify with FDA and the manufacturer before acting.